Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (11-20 of 274) with videos related to

Pageof 28
Sort By:
Blood|July 3, 2025
Interferon-γ sparks inflammatory fire in Castleman diseaseFrits van Rhee, David Fajgenbaum
Blood|May 2, 2024
Insights into the etiology of Castleman diseaseFrits van Rhee, David Fajgenbaum
Hematology/Oncology Clinics of North America|November 22, 2017
Castleman DiseaseFrits van Rhee, Nikhil C Munshi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2023
Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 TrialSamer Al Hadidi, Frits van Rhee
Cancer Treatment and Research|October 4, 2016
Transplantation for Multiple MyelomaYogesh S Jethava, Frits van Rhee
Nature Reviews. Clinical Oncology|October 29, 2014
Haematological cancer: Optimizing the treatment of multiple myelomaGareth J Morgan, Frits van Rhee
British Journal of Haematology|March 16, 2004
Treatment advances in multiple myelomaGuido Tricot, Bart Barlogie, Frits Van Rhee
Hematology/Oncology Clinics of North America|November 22, 2017
Treatment of Idiopathic Castleman DiseaseFrits van Rhee, Amy Greenway, Katie Stone
Blood|June 5, 2014
The future of autologous stem cell transplantation in myelomaFrits van Rhee, Sergio Giralt, Bart Barlogie
Leukemia & Lymphoma|October 31, 2006
NY-ESO-1 immunotherapy for multiple myelomaSusann Szmania, Guido Tricot, Frits van Rhee
Pageof 28

Showing results (11-20 of 274) with videos related to

Sort By:
Pageof 28
Blood|July 3, 2025
Interferon-γ sparks inflammatory fire in Castleman diseaseFrits van Rhee, David Fajgenbaum
Blood|May 2, 2024
Insights into the etiology of Castleman diseaseFrits van Rhee, David Fajgenbaum
Hematology/Oncology Clinics of North America|November 22, 2017
Castleman DiseaseFrits van Rhee, Nikhil C Munshi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2023
Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 TrialSamer Al Hadidi, Frits van Rhee
Cancer Treatment and Research|October 4, 2016
Transplantation for Multiple MyelomaYogesh S Jethava, Frits van Rhee
Nature Reviews. Clinical Oncology|October 29, 2014
Haematological cancer: Optimizing the treatment of multiple myelomaGareth J Morgan, Frits van Rhee
British Journal of Haematology|March 16, 2004
Treatment advances in multiple myelomaGuido Tricot, Bart Barlogie, Frits Van Rhee
Hematology/Oncology Clinics of North America|November 22, 2017
Treatment of Idiopathic Castleman DiseaseFrits van Rhee, Amy Greenway, Katie Stone
Blood|June 5, 2014
The future of autologous stem cell transplantation in myelomaFrits van Rhee, Sergio Giralt, Bart Barlogie
Leukemia & Lymphoma|October 31, 2006
NY-ESO-1 immunotherapy for multiple myelomaSusann Szmania, Guido Tricot, Frits van Rhee
Pageof 28